COPENHAGEN, August 16, 2026, 13:40 CEST
- Novo Nordisk shares fell 2.9% last week despite a raised 2026 outlook.
- The analyst consensus target offers only 2.2% upside from Friday’s close.
- Eleven of 14 tracked analysts rate the stock Hold.
Novo Nordisk NYSE:NVO shares lost 2.9% last week, closing Friday at $45.89. The decline came after management raised its 2026 outlook on August 4. That gap is the clearest signal for investors: better near-term execution has not yet settled the longer-term growth debate.
Wall Street sees little room for error. The average target is $46.89, only 2.2% above Friday’s close. Eleven of 14 analysts recommend holding the shares.
| Date | Close | Daily move | Volume |
|---|---|---|---|
| Aug. 10 | $47.73 | +0.99% | 10.10 million |
| Aug. 11 | $47.17 | -1.17% | 7.80 million |
| Aug. 12 | $46.39 | -1.65% | 9.48 million |
| Aug. 13 | $46.72 | +0.71% | 10.13 million |
| Aug. 14 | $45.89 | -1.78% | 10.81 million |
The operating update was solid. Second-quarter sales rose 3% at constant exchange rates. Adjusted operating profit increased 11% on a reported basis. First-half sales reached DKK175.3 billion.
| Measure | Result | Growth or range |
|---|---|---|
| Q2 sales | DKK78.49 billion | +3% at CER |
| Q2 adjusted operating profit | DKK33.39 billion | +11% reported |
| H1 sales | DKK175.31 billion | +18% at CER |
| 2026 adjusted sales growth | Raised outlook | 0% to -6% at CER |
| 2026 adjusted operating profit growth | Raised outlook | 0% to -6% at CER |
Wegovy remains the hinge. The oral version passed five million U.S. prescriptions after its January launch. European regulators also approved the 7.2-mg injection and the pill in July.
Chief Executive Mike Doustdar said the obesity market would not be a “winner-take-all” contest. He expects products to serve different patient groups. Novo holds about 90% of the oral GLP-1 market, he told Reuters. Reuters
That view matters as Eli Lilly NYSE:LLY expands its obesity franchise. Doustdar said pills could represent half of the market by 2030. The broader market may reach about $100 billion.
| Metric | 2026 estimate | 2027 estimate |
|---|---|---|
| Revenue | DKK296.72 billion | DKK304.53 billion |
| Revenue growth | -3.99% | +2.63% |
| EPS | DKK21.19 | DKK21.84 |
| EPS growth | -7.98% | +3.05% |
The estimates explain the muted valuation response. Analysts still forecast lower 2026 revenue and earnings. Growth returns in 2027, but only modestly under current forecasts.
Novo’s market value is about $201.9 billion. The shares trade at 14.9 times forward earnings. Friday’s close also sat below both the 50-day and 200-day averages.
| Analyst | Firm | Latest action | Target |
|---|---|---|---|
| Evan Seigerman | BMO Capital | Hold, Aug. 12 | $47 |
| Kerry Holford | Berenberg | Downgrade to Hold, Aug. 12 | $47 from $50 |
| James Quigley | Goldman Sachs | Hold, Aug. 7 | $44 from $48 |
| Jasper Hellweg | Argus | Hold, Aug. 7 | Not stated |
| Michael Nedelcovych | TD Cowen | Hold, June 29 | $42 |
The week ahead starts with the ADR trading ex-dividend on Monday, August 17. Payment is scheduled for August 25. Investors will also watch prescription momentum and competitor updates.
The next major company event is Capital Markets Day on September 20 and 21. Third-quarter results follow on November 4. Those events should test whether the prescription surge can turn into durable earnings growth.
Risks: Pricing pressure, reimbursement limits and faster gains by Lilly could weaken forecasts. Stronger pill adoption or improved U.S. access could lift them.
